By inactivating mammalian target of rapamycin/p70 ribosomal S6 kinase 1/Mcl-1 (mTOR/S6K1/Mcl-1) pathway, evodiamine and erlotinib acted in synergy in inhibiting cell proliferation and increasing apoptosis in NSCLC cells (NCI-H460, NCI-H1299, NCI-H1650, and A549) with wild-type EGFR [39] (Figure 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.